An illustration of the new gene editing method, which uses a bridge RNA (yellow) and a recombinase enzyme (blue) to combine two pieces of DNA (Credit: Visual Science)

June 26, 2024 01:13 PM EDTUpdated 01:42 PM

Scientists unveil new way to make large changes to genes, and no CRISPR is required

Ryan Cross

Senior Science Correspondent

Scientists led by Patrick Hsu at the Arc Institute in Palo Alto have unveiled a new form of gene editing that can add, remove or …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Scientists unveil new way to make large changes to genes, and no CRISPR is required

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Why the Supreme Court's overrule of Chevron has major implications for the FDA

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

Supreme Court narrowly rejects Purdue bankruptcy plan, says it gives Sacklers too much protection

Biopharma leaders charting a path for the industry's LGBTQ+ community

GSK’s manufacturing sites in Singapore will use 100% renewable energy by 2025

Sci­en­tists un­veil new way to make large changes to genes, and no CRISPR is re­quired

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

more like this

Why the Supreme Court's over­rule of Chevron has ma­jor im­pli­ca­tions for the FDA

J&J de­tails Phase 3 suc­cess of au­toim­mune dis­ease drug, tout­ing broad­er range than ar­genx’s Vyv­gart

FDA re­jects Rock­et Phar­ma’s ul­tra-rare im­mune dis­ease gene ther­a­py over man­u­fac­tur­ing

Supreme Court nar­row­ly re­jects Pur­due bank­rupt­cy plan, says it gives Sack­lers too much pro­tec­tion

Bio­phar­ma lead­ers chart­ing a path for the in­dus­try's LGBTQ+ com­mu­ni­ty

GSK’s man­u­fac­tur­ing sites in Sin­ga­pore will use 100% re­new­able en­er­gy by 2025

Scientists unveil new way to make large changes to genes, and no CRISPR is required

Why the Supreme Court's overrule of Chevron has major implications for the FDA

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

Supreme Court narrowly rejects Purdue bankruptcy plan, says it gives Sacklers too much protection

Biopharma leaders charting a path for the industry's LGBTQ+ community

GSK’s manufacturing sites in Singapore will use 100% renewable energy by 2025